Search Results for "Actiq"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Actiq. Results 1 to 7 of 7 total matches.
See also: fentanyl
In Brief: Fentanyl Sublingual Tablets (Abstral) for Breakthrough Cancer Pain
The Medical Letter on Drugs and Therapeutics • May 16, 2011 (Issue 1364)
, $16.88-43.19
Actiq (Cephalon) 800, 1200, 43.20-123.41
1600 mcg
lozenges
Sublingual tablet
Abstral ...
The FDA has approved the marketing of fentanyl sublingual tablets (Abstral – ProStrakan) for treatment of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. It is the fourth transmucosal formulation of fentanyl to become available in the US for this indication.1-3The manufacturer recommends an initial dose of 100 mcg, a maximum of 2 doses per breakthrough pain episode, and use for no more than 4 breakthrough pain episodes per day. As with all formulations of fentanyl, strong inhibitors of CYP3A4 such as clarithromycin (Biaxin, and others)...
Fentanyl Nasal Spray (Lazanda) for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
, 400, 600, $16.52
Actiq (Cephalon) 800, 1200, 1600 mcg 46.94
Sublingual tablet
Abstral (ProStrakan ...
The FDA has approved a nasal spray formulation of
fentanyl (Lazanda – Archimedes) for management of
breakthrough pain in adult cancer patients who are
already receiving and are tolerant to opioid therapy.
Fentanyl is already available in the US for intravenous,
intrathecal, epidural, transdermal and oral transmucosal
use.
Fentanyl Buccal Soluble Film (Onsolis) for Breakthrough Cancer Pain
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010 (Issue 1336)
lozenges –
generic OTFC 200, 400, 600, 800, 1200, $16.25-55.44
Actiq (Cephalon) 1600 mcg 37.20-109.56 ...
Fentanyl buccal soluble film (Onsolis – Meda) has been approved by the FDA for treatment of breakthrough pain in adult cancer patients who are already taking and are tolerant to around-the-clock opioid therapy. It is designated as a Schedule II controlled substance Two other oral transmucosal formulations of fentanyl are already available for this indication.
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
for opioid-naive patients
Actiq, Fentora, Lazanda, and Subsys are indicated only for
breakthrough pain ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain
The Medical Letter on Drugs and Therapeutics • Sep 24, 2007 (Issue 1270)
with cancer. An oral transmucosal fentanyl
lozenge on a stick (Actiq, and others) is also available ...
The FDA has approved a transmucosal tablet formulation of fentanyl citrate (Fentora - Cephalon) for management of breakthrough pain in opioid-tolerant patients with cancer. An oral transmucosal fentanyl lozenge on a stick (Actiq, and others) is also available for this indication, and is widely used off-label for chronic, non-cancer pain as well.
Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain
The Medical Letter on Drugs and Therapeutics • May 14, 2012 (Issue 1390)
(Insys) 100, 200, 400, 600, $21.44
800 mcg4
Lozenge
OTFC – generic 200, 400, 600, 13.20
Actiq ...
The FDA has approved a sublingual spray formulation of
fentanyl (Subsys – Insys) for management of breakthrough
pain in adult cancer patients who are receiving
and are tolerant to opioid therapy (taking ≥60 mg/day of
oral morphine or the equivalent). Fentanyl is already
available in the US for intravenous, intrathecal, epidural,
transdermal and transmucosal use.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
Not recommended for opioid-naive patients
Actiq, Fentora, Lazanda, and Subsys are
indicated only ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.